scholarly journals Anal Adenocarcinoma

2020 ◽  
Author(s):  
Keyword(s):  
Anal Adenocarcinoma

Comparative Survival of Patients With Anal Adenocarcinoma, Squamous Cell Carcinoma of the Anus, and Rectal Adenocarcinoma

2016 ◽  
Vol 15 (1) ◽  
pp. 47-53 ◽  
Author(s):  
Robert A. Franklin ◽  
Smith Giri ◽  
Poojitha Valasareddy ◽  
Lindsey T. Lands ◽  
Mike G. Martin
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Rectal Adenocarcinoma ◽  
Anal Adenocarcinoma

Almost Everything I Know About Anal Adenocarcinoma I Learned From Rectal Cancer

2020 ◽  
Vol 16 (10) ◽  
pp. 641-642
Author(s):  
Kelsey A. Klute ◽  
Jennifer A. Leinicke
Keyword(s):  
Rectal Cancer ◽  
Anal Adenocarcinoma

Mucinous anal adenocarcinoma invading the perianal region

2015 ◽  
Vol 30 (10) ◽  
pp. 1429-1430 ◽  
Author(s):  
Laura Iliescu ◽  
Mugur Grasu ◽  
Vlad Herlea ◽  
Constantin D. Ungureanu ◽  
Letitia Toma
Keyword(s):  
Perianal Region ◽  
Anal Adenocarcinoma

scholarly journals Anal adenocarcinoma: Treatment outcomes and trends in a rare disease entity

2019 ◽  
Vol 8 (8) ◽  
pp. 3855-3863
Author(s):  
Rodney E. Wegner ◽  
Richard J. White ◽  
Shaakir Hasan ◽  
Moses Raj ◽  
Dulabh Monga ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Rare Disease ◽  
Disease Entity ◽  
Anal Adenocarcinoma

Case of anal adenocarcinoma in situ with pagetoid spread but without macroscopic abnormality in anal mucosa

2016 ◽  
Vol 44 (9) ◽  
pp. 1076-1077 ◽  
Author(s):  
Takae Shimizu ◽  
Takashi Inozume ◽  
Machiko Takaki ◽  
Takehiro Ohnuma ◽  
Shinya Sano ◽  
...  
Keyword(s):  
Adenocarcinoma In Situ ◽  
Anal Adenocarcinoma ◽  
Pagetoid Spread

Treatment of colorectal cancers with minimally invasive surgical techniques at a dedicated cancer center.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 549-549 ◽  
Author(s):  
Sanjay S. Reddy ◽  
Elin R. Sigurdson ◽  
Jeffrey M. Farma
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Adjuvant Therapy ◽  
Neoadjuvant Treatment ◽  
Surgical Techniques ◽  
Sigmoid Resection ◽  
Cancer Center ◽  
Prior Therapy ◽  
Anal Adenocarcinoma ◽  
Estimated Blood Loss

549 Background: Laparoscopic (LS) and robotic surgery (RS) for colorectal cancer provides a new perspective of the deep pelvis. Our goal was to identify the role of LS and RS for patients with sigmoid and rectal cancer. Methods: We retrospectively analyzed 53 patients treated from 2007-2012. Resection type, previous surgery, neoadjuvant and adjuvant therapy, timing of surgery, lymph nodes (LN) harvested, estimated blood loss (EBL), operative time (OT), complications, and pathology were reviewed. Results: Of 53 patients, 32 underwent LS, and 18 RS. There were 47 patients with adenocarcinoma, 5 with unresectable polyps and 1 with anal melanoma. 62% of patients underwent a recto-sigmoid resection, 23% rectal, and 8% sigmoid. 32% had prior surgery. Neoadjuvant treatment (NAT) was initiated in 31 patients; 3 received chemotherapy without radiation, and 1 short course radiation. An average of 12.8 and 8.4 LN were harvested in the LS and RS groups respectively, with a mean of 9.9 LN after NAT, and 13.9 without. EBL was 155ml (20-650) with LS and 178ml (25-600) with RS. 3 LS cases were converted to an open procedure. Median OT was 270 and 302 minutes for LS and RS groups. Using the Clavien grading system, 12 patients had grade 1-2 complications, 5 grade 3, and 2 grade 4’s within 30 days. Radial margins were positive in 2 patients; one received NAT for a fungating anal adenocarcinoma, and the other had chemotherapy alone. One patient had a positive proximal margin with no prior therapy. Rate of complete pathological response (pCR) was 35%, and 71% were down staged. The mean interval between completion of NAT and resection was 8 weeks (range 4-12), and surgery to adjuvant therapy was 8 weeks (range 4-22). Conclusions: LS and RS surgery for colorectal cancer can be safely performed in conjunction with neoadjuvant and/or adjuvant chemotherapy. NAT should not preclude adoption of these techniques, as we achieved a 35% pCR with minimal operative morbidity allowing patients to proceed to adjuvant chemotherapy in a timely fashion. [Table: see text]

Primary anal adenocarcinoma: a caution for conservative treatment

2006 ◽  
Vol 5 (4) ◽  
pp. 233-236
Author(s):  
J. Martin ◽  
S. Y. K. Ngan ◽  
T. Leong
Keyword(s):  
Clinical Response ◽  
Residual Disease ◽  
Pathological Examination ◽  
Complete Clinical Response ◽  
Resonance Imaging ◽  
Node Metastasis ◽  
Anal Adenocarcinoma ◽  
Positron Emission ◽  
Resection Specimen

There is evidence that a conservative approach with chemoradiotherapy can achieve long-term local control in patients with anal adenocarcinoma. Identification of suitable patients for this approach remains a problem. We describe a patient with a clinically staged T2N0 tumour, who achieved a complete clinical response on magnetic resonance imaging and positron emission tomography after chemoradiotherapy, but was noted to have residual disease with evidence of lymph node metastasis on pathological examination in the abdominoperineal resection specimen. A complete clinical response does not necessarily equate to pathological response.

Sign in / Sign up

Export Citation Format

Share Document